Johnson & Johnson ($JNJ) persuaded the Louisiana Supreme Court to toss a $257 million verdict against the company in a Risperdal marketing case, a big win in the company's multibillion-dollar fight with state and federal authorities. A Louisiana jury had held J&J liable for deceptively marketing Risperdal, a powerful antipsychotic drug, to doctors in the state, but the justices determined that the state hadn't presented sufficient evidence to show J&J had duped doctors into prescribing Risperdal over rival drugs. Report